Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06623110 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of RP2 as Immunoprevention in High-Risk Oral Precancerous Disease
A Phase 2 study of High-Risk Oral Precancerous Disease, sponsored by Glenn J. Hanna.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 2
- Study locations
NCT06623110 is a Phase 2 study of High-Risk Oral Precancerous Disease that is actively recruiting participants, run by Glenn J. Hanna. The registered enrollment target is 25 participants. The trial reports 2 study locations across 1 state.
The verdict
NCT06623110, a Phase 2 study of High-Risk Oral Precancerous Disease, is actively recruiting participants, sponsored by Glenn J. Hanna.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this study is to understand the safety, tolerability, and potential efficacy of an injected immune therapy called RP2 to treat oral precancer conditions and prevent progression to an oral cancer. The name of the study drug involved in this study is: -RP2 (a genetically modified live Herpes Simplex V-1 strain)
Conditions Studied
Interventions
- BIOLOGICAL RP2 Injection
Study Locations (2)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2025-01-01 |
| Est. Completion | 2029-01-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06623110
The ClinicalTrials.gov registry entry for NCT06623110 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Glenn J. Hanna, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with High-Risk Oral Precancerous Disease appearing as the primary indexed condition, and to 1 intervention - of which RP2 Injection is the first listed.
NCT06623110 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06623110 about?
NCT06623110 is a clinical study titled "Phase II Study of RP2 as Immunoprevention in High-Risk Oral Precancerous Disease". The goal of this study is to understand the safety, tolerability, and potential efficacy of an injected immune therapy called RP2 to treat oral precancer conditions and prevent progression to an oral cancer. The name of the study drug involved in this study is: -RP2 (a genetically modified live He...
What is the current status of trial NCT06623110?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2025-01-01. Estimated completion is 2029-01-01.
What conditions does trial NCT06623110 study?
This clinical trial studies the following conditions: High-Risk Oral Precancerous Disease.
What interventions are being tested in trial NCT06623110?
The interventions under investigation include: RP2 Injection (BIOLOGICAL).
Who is sponsoring clinical trial NCT06623110?
This trial is sponsored by Glenn J. Hanna, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06623110 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.